Although many of these signaling pathways were still predicted to be enriched in the tumor-reverted hepatocytes (RFP+R), the majority of them were no longer predicted to be deregulated (Fig. 6, gray, no trend of activation or inhibition), except for Gα12/13 (α subunits of heterotrimeric G proteins G12 and G13), NGF (Nerve growth factor), Thrombopoietin, mouse embryonic stem cell pluripotency and EIF2 (Eukaryotic initiation factor 2) signaling. This evidence concerns the gene NGF and neoplasm.